Articles from RENEXXION IRELAND

ROSCREA, Ireland, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited ("Renexxion"), a private biopharmaceutical company focused on advancing new therapies for patients with significant unmet needs in gastrointestinal ("GI") disorders, announced that the United States Patent and Trademark Office ("USPTO") has granted its sixth U.S. patent for naronapride. The patent (Patent No. 12,391,684) encompasses pharmaceutical composition having a trihydrate form of naronapride and related dosage forms and methods of use for treating a range of GI disorders.

ROSCREA, Ireland and FREIBURG, Germany, May 27, 2025 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, in collaboration with its partner Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), today announced the successful completion of patient enrollment for the global Phase 2b MOVE-IT study (ClinicalTrials.gov ID: NCT05621811) evaluating the safety and efficacy of naronapride for the treatment of gastroparesis. The MOVE-IT study achieved its target enrolment of 320 patients, with topline results expected in the second half of 2025.

ROSCREA, Ireland, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company dedicated to delivering innovative treatments for patients with significant unmet needs in gastrointestinal (“GI”) disorders, is pleased to announce a major milestone in its intellectual property portfolio. The United States Patent and Trademark Office (“USPTO”) has granted the fifth patent (Patent No. 12,098,149) in a comprehensive series, securing broad protection for a novel crystal isoform of naronapride, Renexxion’s lead compound, and its use in the treatment of GI disorders.